ASTRAZENECA PLC ORD USD0.25
Symbol: AZN
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Charts
Company
Business Summary
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.
Financial Summary
BRIEF: For the three months ended 31 March 2024, AstraZeneca plc revenues increased 17% to $12.68B. Net income increased 21% to $2.18B. Revenues reflect Farxiga segment increase of 42% to $1.85B, Imfinzi segment increase of 24% to $1.11B, United States segment increase of 19% to $5.12B, Europe segment increase of 22% to $2.63B. Net income benefited from Impairment of Intangibles Excl Goodwil decrease from $271M (expense) to $0K.
Financials
Income Statement - All values are in GBP (M).
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
---|---|---|---|---|---|---|
Total Revenue | 45,811.00 | 44,351.00 | 37,417.00 | 26,617.00 | 24,384.00 | 22,090.00 |
Gross profit | 37,743.00 | 35,702.00 | 27,875.00 | 21,347.00 | 19,560.00 | 17,844.00 |
Operating Profit/Loss | 8,193.00 | 3,757.00 | 1,056.00 | 5,162.00 | 2,924.00 | 3,387.00 |
Profit Before Tax | 6,899.00 | 2,501.00 | -265.00 | 3,916.00 | 1,548.00 | 1,993.00 |
Profit After Tax | 5,961.00 | 3,293.00 | 115.00 | 3,144.00 | 1,227.00 | 2,050.00 |
Equity Holders of Parent Company | 5,955.00 | 3,288.00 | 112.00 | 3,196.00 | 1,335.00 | 2,155.00 |
Minority Interest | 17.00 | 16.00 | 16.00 | 68.00 | 1,577.00 | 1,681.00 |
Balance Sheet - All values are in GBP (M).
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
---|---|---|---|---|---|---|
Total Non-Current Assets | 76,065.00 | 73,890.00 | 79,119.00 | 47,185.00 | 45,814.00 | 45,060.00 |
Total Current Assets | 25,054.00 | 22,593.00 | 26,244.00 | 19,544.00 | 15,563.00 | 15,591.00 |
Total Assets | 101,119.00 | 96,483.00 | 105,363.00 | 66,729.00 | 61,377.00 | 60,651.00 |
Total Liabilities | 61,953.00 | 59,425.00 | 66,076.00 | 51,091.00 | 46,781.00 | 46,607.00 |
Total Net Assets | 39,166.00 | 37,058.00 | 39,287.00 | 15,638.00 | 14,596.00 | 14,044.00 |
Shareholders Funds | 39,143.00 | 37,037.00 | 39,268.00 | 15,622.00 | 13,127.00 | 12,468.00 |
Minority Interests | 17.00 | 16.00 | 16.00 | 68.00 | 1,577.00 | 1,681.00 |
Total Equity | 39,166.00 | 37,058.00 | 39,287.00 | 15,638.00 | 14,596.00 | 14,044.00 |
Outlook
Broker View
Data shown is based on the past 75 days of broker views.
ActionBrokers |
Strong Buy8 |
Buy15 |
Neutral5 |
Sell0 |
Strong Sell1 |
---|---|---|---|---|---|
Brokers | 8 | 15 | 5 | 0 | 1 |
Consensus |
ConsensusBuy |
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
Forecasts
Year | 2024 | 2025 | 2026 |
---|---|---|---|
Revenue | £50,780.10mn | £54,552.10mn | £57,452.00mn |
Pre-tax-Profit | £15,628.50mn | £17,651.90mn | £19,584.20mn |
EPS | £6.50p | £7.39p | £8.06p |
EPS Growth | 111.62% | 13.66% | 9.09% |
P/E | 18.73 | 16.48 | 15.1 |
PEG Ratio | 0.17 | 1.21 | 1.66 |
Dividend | 248.26p | 260.54p | 271.88p |
Yield | 0.00% | 0.00% | 0.00% |
Upgrades & Downgrades (Latest)
Date | Broker | Recommendation | Price | Old Target | New Target | Change |
---|---|---|---|---|---|---|
23rd Apr 2024 | Deutsche | Reiteration | 11268p | 0p | 10500p | Hold |
15th Apr 2024 | Deutsche | Upgrade | 11024p | 0p | 0p | Hold |
15th Apr 2024 | Shore Capital | Reiteration | 11024p | 0p | 0p | Buy |
8th Apr 2024 | Barclays | Reiteration | 10610p | 0p | 12500p | Overweight |
5th Apr 2024 | Shore Capital | Reiteration | 10620p | 0p | 0p | Buy |
4th Apr 2024 | JP Morgan Cazenove | Reiteration | 10736p | 0p | 1300p | Overweight |
13th Mar 2024 | Berenberg Bank | Reiteration | 10458p | 0p | 120p | Buy |
12th Mar 2024 | Deutsche | Reiteration | 10436p | 0p | 0p | Sell |
27th Feb 2024 | Deutsche | Reiteration | 10328p | 0p | 9500p | Sell |
20th Feb 2024 | JP Morgan Cazenove | Reiteration | 10204p | 0p | 12500p | Overweight |
Time & Sales
All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.
Date | Time | Price | Volume | Type |
---|---|---|---|---|
3 May 2024 | 10:02 | 12,036 | 2 | Sell |
3 May 2024 | 10:02 | 12,036 | 25 | Sell |
3 May 2024 | 10:02 | 12,037.98 | 4 | Buy |
3 May 2024 | 10:02 | 12,036.197 | 3 | Sell |
3 May 2024 | 10:02 | 12,038 | 10 | Sell |
3 May 2024 | 10:02 | 12,038 | 29 | Sell |
3 May 2024 | 10:02 | 12,038 | 42 | Sell |
3 May 2024 | 10:02 | 12,038 | 69 | Sell |
3 May 2024 | 10:01 | 12,040 | 14 | Sell |
3 May 2024 | 10:01 | 12,040 | 3 | Sell |
3 May 2024 | 10:01 | 12,040 | 25 | Sell |
3 May 2024 | 10:01 | 12,040 | 64 | Sell |
3 May 2024 | 10:01 | 12,040 | 6 | Sell |
3 May 2024 | 10:01 | 12,040 | 5 | Sell |
3 May 2024 | 10:01 | 12,040 | 25 | Sell |
3 May 2024 | 10:01 | 12,040 | 49 | Sell |
3 May 2024 | 10:01 | 12,040 | 112 | Sell |
3 May 2024 | 10:01 | 12,040 | 213 | Sell |
3 May 2024 | 10:01 | 12,040 | 143 | Sell |
3 May 2024 | 10:01 | 12,040 | 37 | Sell |
Selected data supplied by Thomson Reuters © View restrictions.